MNOV

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Clinical Trial Update: MediciNova, Inc. announced positive interim analysis results from its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) for ALS, showing strong correlations in patient data over 6 and 12 months, with the trial continuing as recommended by an independent Data Safety Monitoring Board.

Company Overview: MediciNova is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, with MN-166 in late-stage trials for ALS and other conditions, while also preparing for a large-scale Expanded Access Program trial next year.

Analyst Ratings Updates: Several Wall Street analysts have initiated coverage on various companies, including MediciNova with a Buy rating and a price target of $9, PROCEPT BioRobotics with an Overweight rating and a target of $105, Viking Therapeutics with an Overweight rating at $74, Autodesk with a Buy rating at $350, and Zoetis with an Outperform rating at $215.

Current Stock Prices: The closing prices for these stocks as of the last trading day were significantly lower than the analysts' targets, with MediciNova at $2.07, PROCEPT BioRobotics at $95.59, Viking Therapeutics at $52.94, Autodesk at $291.90, and Zoetis at $175.25.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Corporate Update from MediciNova: MediciNova, Inc. is focused on developing novel anti-inflammatory treatments and has announced collaborations for clinical trials of its compound MN166 (ibudilast) for ALS and Long COVID, aiming to minimize cash expenses while maximizing shareholder value.

Financial Position and Future Outlook: The company maintains a strong cash position of $42.3 million as of September 30, 2024, and plans to provide regular updates to shareholders, emphasizing transparency and strategic partnerships to enhance its clinical development pipeline.

Patent Allowance Announcement: MediciNova, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering a method to decrease triglyceride synthesis in the liver using MN-001 (Tipelukast), which is beneficial for patients with insulin resistance, pre-diabetes, or diabetes.

Company Overview and Future Plans: MediciNova is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic disorders, with ongoing clinical trials for MN-001 and other compounds aimed at treating various diseases, including ALS and non-alcoholic fatty liver disease.

Clinical Trial Update: MediciNova, Inc. presented an update on its Phase 2/3 clinical trial of MN-166 (ibudilast) for ALS patients at the 2024 Annual NEALS Meeting, discussing study design, objectives, and enrollment progress.

Company Overview: MediciNova is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, with MN-166 in late-stage trials for ALS and other conditions, while also pursuing multiple clinical programs across various diseases.

Clinical Trial Presentation: MediciNova, Inc. announced that an abstract for its clinical trial of MN-166 (ibudilast) in treating Amyotrophic Lateral Sclerosis (ALS) has been accepted for a poster presentation at the 35th International Symposium on ALS/MND in December 2024.

Company Overview: MediciNova is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, with its lead asset MN-166 currently in late-stage clinical development for ALS and other conditions.

Clinical Trial Presentation: MediciNova, Inc. announced that an abstract for the COMBAT-ALS Phase 2b/3 study of MN-166 (ibudilast) in ALS has been accepted for presentation at the 2024 Annual NEALS Meeting on October 23, 2024, by lead investigator Dr. Björn Oskarsson.

Company Overview: MediciNova is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, with MN-166 currently in late-stage clinical trials for ALS and other conditions, while also pursuing multiple programs across various indications.

Stock Performance Overview: Recursion Pharmaceuticals saw an 11.6% drop in shares following the announcement of Phase 2 data for a treatment, while Nikola's shares fell 10.4%. Conversely, Sify Technologies surged 103% after achieving NVIDIA certification, and several other companies experienced significant gains.

Market Losers: Windtree Therapeutics faced a 42.2% decline, with Dyne Therapeutics and Agape ATP also experiencing substantial drops of 31.7% and 31.3%, respectively, amidst various announcements regarding clinical trials and company transitions.

Market Performance: Health care stocks experienced a decline, with the NYSE Health Care Index down 0.1% and notable drops in various ETFs, while MediciNova and BridgeBio Pharma saw significant gains due to positive corporate news.

Corporate Developments: MediciNova's shares rose over 11% after announcing a US patent for its drug MN-166, while BridgeBio Pharma's stock surged over 13% following promising phase 3 study results; conversely, NuCana's shares plummeted 48% after halting its colorectal cancer drug trials.

Health Care Stock Performance: Health care stocks saw a slight increase, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund (XLV) gaining 0.3%, while the iShares Biotechnology ETF (IBB) fell by 0.2%.

Corporate News Highlights: Novavax shares rose nearly 9% after receiving FDA emergency use authorization for its updated COVID-19 vaccine, while Work Medical Technology shares surged over 21% due to IPO activity; in contrast, NuCana's shares plummeted 54% after halting phase 2 testing of its colorectal cancer drug.

Patent Win for MediciNova: MediciNova's shares rose approximately 9% after the U.S. Patent and Trademark Office granted a notice of allowance for a patent related to its long COVID treatment candidate, MN-166 (ibudilast), which is expected to be valid until at least November 2042.

Ongoing Clinical Trials: A Phase 2/3 trial named Reclaim is currently in progress for ibudilast in collaboration with the University Health Network in Canada, aimed at supporting regulatory submissions to Health Canada for the drug's use in treating post-COVID conditions.

Patent Approval: MediciNova, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering MN-166 (ibudilast) to treat various post-COVID conditions, with expected patent expiration no earlier than November 2042.

Clinical Development: MN-166 is in late-stage clinical trials for neurodegenerative diseases and Long COVID, with plans to apply for New Drug Application upon positive study outcomes, highlighting MediciNova's commitment to addressing health challenges related to COVID-19.